Global Neuroendocrine Tumor Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Neuroendocrine Tumor Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Neuroendocrine Tumor Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Neuroendocrine Tumor Drug by Country/Region, 2017, 2022 & 2028

2.2 Neuroendocrine Tumor Drug Segment by Type

2.2.1 mTOR Protein Inhibitors

2.2.2 Tyrosine Kinase 3 Inhibitors

2.2.3 Somatostatin Receptor Antagonists

2.2.4 Growth Hormone Releasing Factor Antagonists

2.2.5 Somatostatin Receptor Agonists

2.2.6 Others

2.3 Neuroendocrine Tumor Drug Sales by Type

2.3.1 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Neuroendocrine Tumor Drug Sale Price by Type (2017-2022)

2.4 Neuroendocrine Tumor Drug Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Neuroendocrine Tumor Drug Sales by Application

2.5.1 Global Neuroendocrine Tumor Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Neuroendocrine Tumor Drug Sale Price by Application (2017-2022)

3 Global Neuroendocrine Tumor Drug by Company

3.1 Global Neuroendocrine Tumor Drug Breakdown Data by Company

3.1.1 Global Neuroendocrine Tumor Drug Annual Sales by Company (2020-2022)

3.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Company (2020-2022)

3.2 Global Neuroendocrine Tumor Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Neuroendocrine Tumor Drug Revenue by Company (2020-2022)

3.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Company (2020-2022)

3.3 Global Neuroendocrine Tumor Drug Sale Price by Company

3.4 Key Manufacturers Neuroendocrine Tumor Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Neuroendocrine Tumor Drug Product Location Distribution

3.4.2 Players Neuroendocrine Tumor Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Neuroendocrine Tumor Drug by Geographic Region

4.1 World Historic Neuroendocrine Tumor Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Neuroendocrine Tumor Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Neuroendocrine Tumor Drug Annual Revenue by Geographic Region

4.2 World Historic Neuroendocrine Tumor Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Neuroendocrine Tumor Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Neuroendocrine Tumor Drug Annual Revenue by Country/Region

4.3 Americas Neuroendocrine Tumor Drug Sales Growth

4.4 APAC Neuroendocrine Tumor Drug Sales Growth

4.5 Europe Neuroendocrine Tumor Drug Sales Growth

4.6 Middle East & Africa Neuroendocrine Tumor Drug Sales Growth

5 Americas

5.1 Americas Neuroendocrine Tumor Drug Sales by Country

5.1.1 Americas Neuroendocrine Tumor Drug Sales by Country (2017-2022)

5.1.2 Americas Neuroendocrine Tumor Drug Revenue by Country (2017-2022)

5.2 Americas Neuroendocrine Tumor Drug Sales by Type

5.3 Americas Neuroendocrine Tumor Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Neuroendocrine Tumor Drug Sales by Region

6.1.1 APAC Neuroendocrine Tumor Drug Sales by Region (2017-2022)

6.1.2 APAC Neuroendocrine Tumor Drug Revenue by Region (2017-2022)

6.2 APAC Neuroendocrine Tumor Drug Sales by Type

6.3 APAC Neuroendocrine Tumor Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Neuroendocrine Tumor Drug by Country

7.1.1 Europe Neuroendocrine Tumor Drug Sales by Country (2017-2022)

7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2022)

7.2 Europe Neuroendocrine Tumor Drug Sales by Type

7.3 Europe Neuroendocrine Tumor Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Neuroendocrine Tumor Drug by Country

8.1.1 Middle East & Africa Neuroendocrine Tumor Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Neuroendocrine Tumor Drug Sales by Type

8.3 Middle East & Africa Neuroendocrine Tumor Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Neuroendocrine Tumor Drug

10.3 Manufacturing Process Analysis of Neuroendocrine Tumor Drug

10.4 Industry Chain Structure of Neuroendocrine Tumor Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Neuroendocrine Tumor Drug Distributors

11.3 Neuroendocrine Tumor Drug Customer

12 World Forecast Review for Neuroendocrine Tumor Drug by Geographic Region

12.1 Global Neuroendocrine Tumor Drug Market Size Forecast by Region

12.1.1 Global Neuroendocrine Tumor Drug Forecast by Region (2023-2028)

12.1.2 Global Neuroendocrine Tumor Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Neuroendocrine Tumor Drug Forecast by Type

12.7 Global Neuroendocrine Tumor Drug Forecast by Application

13 Key Players Analysis

13.1 Eisai

13.1.1 Eisai Company Information

13.1.2 Eisai Neuroendocrine Tumor Drug Product Offered

13.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Eisai Main Business Overview

13.1.5 Eisai Latest Developments

13.2 Exelixis, Inc.

13.2.1 Exelixis, Inc. Company Information

13.2.2 Exelixis, Inc. Neuroendocrine Tumor Drug Product Offered

13.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Exelixis, Inc. Main Business Overview

13.2.5 Exelixis, Inc. Latest Developments

13.3 Foresee Pharmaceuticals, LLC

13.3.1 Foresee Pharmaceuticals, LLC Company Information

13.3.2 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Offered

13.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Foresee Pharmaceuticals, LLC Main Business Overview

13.3.5 Foresee Pharmaceuticals, LLC Latest Developments

13.4 Hutchison MediPharma Limited

13.4.1 Hutchison MediPharma Limited Company Information

13.4.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Offered

13.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Hutchison MediPharma Limited Main Business Overview

13.4.5 Hutchison MediPharma Limited Latest Developments

13.5 Intezyne, Inc

13.5.1 Intezyne, Inc Company Information

13.5.2 Intezyne, Inc Neuroendocrine Tumor Drug Product Offered

13.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Intezyne, Inc Main Business Overview

13.5.5 Intezyne, Inc Latest Developments

13.6 INVENT Pharmaceuticals, Inc.

13.6.1 INVENT Pharmaceuticals, Inc. Company Information

13.6.2 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Offered

13.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 INVENT Pharmaceuticals, Inc. Main Business Overview

13.6.5 INVENT Pharmaceuticals, Inc. Latest Developments

13.7 Ipsen S.A.

13.7.1 Ipsen S.A. Company Information

13.7.2 Ipsen S.A. Neuroendocrine Tumor Drug Product Offered

13.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Ipsen S.A. Main Business Overview

13.7.5 Ipsen S.A. Latest Developments

13.8 Jiangsu Hengrui Medicine Co., Ltd.

13.8.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information

13.8.2 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Offered

13.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Jiangsu Hengrui Medicine Co., Ltd. Main Business Overview

13.8.5 Jiangsu Hengrui Medicine Co., Ltd. Latest Developments

13.9 Karyopharm Therapeutics, Inc.

13.9.1 Karyopharm Therapeutics, Inc. Company Information

13.9.2 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Offered

13.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Karyopharm Therapeutics, Inc. Main Business Overview

13.9.5 Karyopharm Therapeutics, Inc. Latest Developments

13.10 Lexicon Pharmaceuticals, Inc.

13.10.1 Lexicon Pharmaceuticals, Inc. Company Information

13.10.2 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Offered

13.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Lexicon Pharmaceuticals, Inc. Main Business Overview

13.10.5 Lexicon Pharmaceuticals, Inc. Latest Developments

13.11 Midatech Pharma Plc .

13.11.1 Midatech Pharma Plc . Company Information

13.11.2 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Offered

13.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Midatech Pharma Plc . Main Business Overview

13.11.5 Midatech Pharma Plc . Latest Developments

13.12 Millennium Pharmaceuticals, Inc.

13.12.1 Millennium Pharmaceuticals, Inc. Company Information

13.12.2 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Offered

13.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Millennium Pharmaceuticals, Inc. Main Business Overview

13.12.5 Millennium Pharmaceuticals, Inc. Latest Developments

13.13 MolMed S.p.A.

13.13.1 MolMed S.p.A. Company Information

13.13.2 MolMed S.p.A. Neuroendocrine Tumor Drug Product Offered

13.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 MolMed S.p.A. Main Business Overview

13.13.5 MolMed S.p.A. Latest Developments

13.14 Northwest Biotherapeutics, Inc.

13.14.1 Northwest Biotherapeutics, Inc. Company Information

13.14.2 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Offered

13.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Northwest Biotherapeutics, Inc. Main Business Overview

13.14.5 Northwest Biotherapeutics, Inc. Latest Developments

13.15 Novartis AG

13.15.1 Novartis AG Company Information

13.15.2 Novartis AG Neuroendocrine Tumor Drug Product Offered

13.15.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Novartis AG Main Business Overview

13.15.5 Novartis AG Latest Developments

13.16 OctreoPharm Sciences GmbH

13.16.1 OctreoPharm Sciences GmbH Company Information

13.16.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Offered

13.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 OctreoPharm Sciences GmbH Main Business Overview

13.16.5 OctreoPharm Sciences GmbH Latest Developments

13.17 OXiGENE, Inc.

13.17.1 OXiGENE, Inc. Company Information

13.17.2 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Offered

13.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 OXiGENE, Inc. Main Business Overview

13.17.5 OXiGENE, Inc. Latest Developments

14 Research Findings and Conclusion

Table 1. Neuroendocrine Tumor Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Neuroendocrine Tumor Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of mTOR Protein Inhibitors

Table 4. Major Players of Tyrosine Kinase 3 Inhibitors

Table 5. Major Players of Somatostatin Receptor Antagonists

Table 6. Major Players of Growth Hormone Releasing Factor Antagonists

Table 7. Major Players of Somatostatin Receptor Agonists

Table 8. Major Players of Others

Table 9. Global Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 10. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2022)

Table 11. Global Neuroendocrine Tumor Drug Revenue by Type (2017-2022) & ($ million)

Table 12. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Neuroendocrine Tumor Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 14. Global Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 15. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2022)

Table 16. Global Neuroendocrine Tumor Drug Revenue by Application (2017-2022)

Table 17. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Neuroendocrine Tumor Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 19. Global Neuroendocrine Tumor Drug Sales by Company (2020-2022) & (K Pcs)

Table 20. Global Neuroendocrine Tumor Drug Sales Market Share by Company (2020-2022)

Table 21. Global Neuroendocrine Tumor Drug Revenue by Company (2020-2022) ($ Millions)

Table 22. Global Neuroendocrine Tumor Drug Revenue Market Share by Company (2020-2022)

Table 23. Global Neuroendocrine Tumor Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 24. Key Manufacturers Neuroendocrine Tumor Drug Producing Area Distribution and Sales Area

Table 25. Players Neuroendocrine Tumor Drug Products Offered

Table 26. Neuroendocrine Tumor Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Neuroendocrine Tumor Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 30. Global Neuroendocrine Tumor Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Neuroendocrine Tumor Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 32. Global Neuroendocrine Tumor Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Neuroendocrine Tumor Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 34. Global Neuroendocrine Tumor Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Neuroendocrine Tumor Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 36. Global Neuroendocrine Tumor Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 38. Americas Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & ($ Millions)

Table 40. Americas Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 42. Americas Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2022)

Table 43. Americas Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 44. Americas Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)

Table 46. APAC Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Neuroendocrine Tumor Drug Revenue by Region (2017-2022) & ($ Millions)

Table 48. APAC Neuroendocrine Tumor Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 50. APAC Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 52. APAC Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 54. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & ($ Millions)

Table 56. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 58. Europe Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 60. Europe Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 62. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & ($ Millions)

Table 64. Middle East & Africa Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 68. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Neuroendocrine Tumor Drug

Table 70. Key Market Challenges & Risks of Neuroendocrine Tumor Drug

Table 71. Key Industry Trends of Neuroendocrine Tumor Drug

Table 72. Neuroendocrine Tumor Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Neuroendocrine Tumor Drug Distributors List

Table 75. Neuroendocrine Tumor Drug Customer List

Table 76. Global Neuroendocrine Tumor Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 77. Global Neuroendocrine Tumor Drug Sales Market Forecast by Region

Table 78. Global Neuroendocrine Tumor Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 79. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Neuroendocrine Tumor Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 81. Americas Neuroendocrine Tumor Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 82. APAC Neuroendocrine Tumor Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 83. APAC Neuroendocrine Tumor Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 84. Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Europe Neuroendocrine Tumor Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Middle East & Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 87. Middle East & Africa Neuroendocrine Tumor Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Global Neuroendocrine Tumor Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 89. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 91. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Neuroendocrine Tumor Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 93. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 95. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. Eisai Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. Eisai Neuroendocrine Tumor Drug Product Offered

Table 98. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 99. Eisai Main Business

Table 100. Eisai Latest Developments

Table 101. Exelixis, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Exelixis, Inc. Neuroendocrine Tumor Drug Product Offered

Table 103. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 104. Exelixis, Inc. Main Business

Table 105. Exelixis, Inc. Latest Developments

Table 106. Foresee Pharmaceuticals, LLC Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Offered

Table 108. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 109. Foresee Pharmaceuticals, LLC Main Business

Table 110. Foresee Pharmaceuticals, LLC Latest Developments

Table 111. Hutchison MediPharma Limited Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Offered

Table 113. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 114. Hutchison MediPharma Limited Main Business

Table 115. Hutchison MediPharma Limited Latest Developments

Table 116. Intezyne, Inc Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Intezyne, Inc Neuroendocrine Tumor Drug Product Offered

Table 118. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 119. Intezyne, Inc Main Business

Table 120. Intezyne, Inc Latest Developments

Table 121. INVENT Pharmaceuticals, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Offered

Table 123. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 124. INVENT Pharmaceuticals, Inc. Main Business

Table 125. INVENT Pharmaceuticals, Inc. Latest Developments

Table 126. Ipsen S.A. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. Ipsen S.A. Neuroendocrine Tumor Drug Product Offered

Table 128. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 129. Ipsen S.A. Main Business

Table 130. Ipsen S.A. Latest Developments

Table 131. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Offered

Table 133. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 134. Jiangsu Hengrui Medicine Co., Ltd. Main Business

Table 135. Jiangsu Hengrui Medicine Co., Ltd. Latest Developments

Table 136. Karyopharm Therapeutics, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Offered

Table 138. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 139. Karyopharm Therapeutics, Inc. Main Business

Table 140. Karyopharm Therapeutics, Inc. Latest Developments

Table 141. Lexicon Pharmaceuticals, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Offered

Table 143. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 144. Lexicon Pharmaceuticals, Inc. Main Business

Table 145. Lexicon Pharmaceuticals, Inc. Latest Developments

Table 146. Midatech Pharma Plc . Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Offered

Table 148. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 149. Midatech Pharma Plc . Main Business

Table 150. Midatech Pharma Plc . Latest Developments

Table 151. Millennium Pharmaceuticals, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Offered

Table 153. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 154. Millennium Pharmaceuticals, Inc. Main Business

Table 155. Millennium Pharmaceuticals, Inc. Latest Developments

Table 156. MolMed S.p.A. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. MolMed S.p.A. Neuroendocrine Tumor Drug Product Offered

Table 158. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 159. MolMed S.p.A. Main Business

Table 160. MolMed S.p.A. Latest Developments

Table 161. Northwest Biotherapeutics, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 162. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Offered

Table 163. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 164. Northwest Biotherapeutics, Inc. Main Business

Table 165. Northwest Biotherapeutics, Inc. Latest Developments

Table 166. Novartis AG Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 167. Novartis AG Neuroendocrine Tumor Drug Product Offered

Table 168. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 169. Novartis AG Main Business

Table 170. Novartis AG Latest Developments

Table 171. OctreoPharm Sciences GmbH Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 172. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Offered

Table 173. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 174. OctreoPharm Sciences GmbH Main Business

Table 175. OctreoPharm Sciences GmbH Latest Developments

Table 176. OXiGENE, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors

Table 177. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Offered

Table 178. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 179. OXiGENE, Inc. Main Business

Table 180. OXiGENE, Inc. Latest Developments

List of Figures

Figure 1. Picture of Neuroendocrine Tumor Drug

Figure 2. Neuroendocrine Tumor Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Neuroendocrine Tumor Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Neuroendocrine Tumor Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Neuroendocrine Tumor Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of mTOR Protein Inhibitors

Figure 10. Product Picture of Tyrosine Kinase 3 Inhibitors

Figure 11. Product Picture of Somatostatin Receptor Antagonists

Figure 12. Product Picture of Growth Hormone Releasing Factor Antagonists

Figure 13. Product Picture of Somatostatin Receptor Agonists

Figure 14. Product Picture of Others

Figure 15. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2021

Figure 16. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2017-2022)

Figure 17. Neuroendocrine Tumor Drug Consumed in Hospital

Figure 18. Global Neuroendocrine Tumor Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 19. Neuroendocrine Tumor Drug Consumed in Clinic

Figure 20. Global Neuroendocrine Tumor Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 21. Neuroendocrine Tumor Drug Consumed in Others

Figure 22. Global Neuroendocrine Tumor Drug Market: Others (2017-2022) & (K Pcs)

Figure 23. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2022)

Figure 24. Global Neuroendocrine Tumor Drug Revenue Market Share by Application in 2021

Figure 25. Neuroendocrine Tumor Drug Revenue Market by Company in 2021 ($ Million)

Figure 26. Global Neuroendocrine Tumor Drug Revenue Market Share by Company in 2021

Figure 27. Global Neuroendocrine Tumor Drug Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Neuroendocrine Tumor Drug Revenue Market Share by Geographic Region in 2021

Figure 29. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2022)

Figure 30. Global Neuroendocrine Tumor Drug Revenue Market Share by Country/Region in 2021

Figure 31. Americas Neuroendocrine Tumor Drug Sales 2017-2022 (K Pcs)

Figure 32. Americas Neuroendocrine Tumor Drug Revenue 2017-2022 ($ Millions)

Figure 33. APAC Neuroendocrine Tumor Drug Sales 2017-2022 (K Pcs)

Figure 34. APAC Neuroendocrine Tumor Drug Revenue 2017-2022 ($ Millions)

Figure 35. Europe Neuroendocrine Tumor Drug Sales 2017-2022 (K Pcs)

Figure 36. Europe Neuroendocrine Tumor Drug Revenue 2017-2022 ($ Millions)

Figure 37. Middle East & Africa Neuroendocrine Tumor Drug Sales 2017-2022 (K Pcs)

Figure 38. Middle East & Africa Neuroendocrine Tumor Drug Revenue 2017-2022 ($ Millions)

Figure 39. Americas Neuroendocrine Tumor Drug Sales Market Share by Country in 2021

Figure 40. Americas Neuroendocrine Tumor Drug Revenue Market Share by Country in 2021

Figure 41. United States Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Canada Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. Mexico Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 44. Brazil Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 45. APAC Neuroendocrine Tumor Drug Sales Market Share by Region in 2021

Figure 46. APAC Neuroendocrine Tumor Drug Revenue Market Share by Regions in 2021

Figure 47. China Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Japan Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. South Korea Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Southeast Asia Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. India Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 52. Australia Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 53. Europe Neuroendocrine Tumor Drug Sales Market Share by Country in 2021

Figure 54. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country in 2021

Figure 55. Germany Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. France Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. UK Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Italy Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Russia Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 60. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Neuroendocrine Tumor Drug Revenue Market Share by Country in 2021

Figure 62. Egypt Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. South Africa Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. Israel Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Turkey Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. GCC Country Neuroendocrine Tumor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Neuroendocrine Tumor Drug in 2021

Figure 68. Manufacturing Process Analysis of Neuroendocrine Tumor Drug

Figure 69. Industry Chain Structure of Neuroendocrine Tumor Drug

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles